Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$1140.00
-23.00 (-1.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-1.1B · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
51/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32.9B
P/E
15.3x
↓EV/EBITDA
5.9x
↓ROE
3.7%
↑Gross Margin
17.1%
↓Debt/Equity
0.23
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
—
FCF margin
-2.2%
FCF / Net income
-0.59x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $50.64B · net income $1.91B · FCF $-1.13B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $50.64B | $50.64B | $46.90B | $45.10B | $43.46B |
| Net Income | $1.91B | $1.91B | $3.29B | $3.60B | $4.67B |
| EBITDA | $7.41B | $7.41B | $7.92B | $8.96B | $10.04B |
| EPS | 63.63 | 63.63 | 105.00 | 113.71 | 152.46 |
| Gross Margin | 17.1% | 17.1% | 21.0% | 22.9% | 26.4% |
| Operating Margin | 5.2% | 5.2% | 8.3% | 11.5% | 15.1% |
| Net Margin | 3.8% | 3.8% | 7.0% | 8.0% | 10.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.23 | 0.23 | 0.17 | 0.10 | 0.07 |
| Current Ratio | 2.50 | 2.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.13B | $-1.13B | $-1.09B | $-1.40B | $-363.0M |
| Returns | |||||
| ROE | 3.7% | 3.7% | 6.3% | 7.1% | 9.9% |
| Valuation | |||||
| P/E | 15.34 | 15.34 | 10.61 | 9.43 | 7.94 |
| EV/EBITDA | 5.92 | 5.92 | 5.17 | 3.93 | 3.60 |
| P/B | 0.66 | 0.66 | 0.67 | 0.67 | 0.78 |
| Growth & Yield | |||||
| Revenue Growth | 8.0% | 8.0% | 4.0% | 3.8% | — |
| EPS Growth | -39.4% | -39.4% | -7.7% | -25.4% | — |
| Dividend Yield | 3.4% | 3.4% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
16.7%
EPS terminal req.
$101.16
Spread vs growth
-56.1%
5Y implied EPS CAGR
14.0%
EPS terminal req.
$122.40
Spread vs growth
-53.4%
10Y implied EPS CAGR
12.0%
EPS terminal req.
$197.12
Spread vs growth
-51.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+11.3%
Start / end P/E
10.1x → 17.9x
EPS bridge
105.00 → 63.63
Residual
-30.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.